Autobio Diagnostics Co

Autobio Diagnostics Co FCF/Debt

The Free Cash Flow to Debt Ratio of Autobio Diagnostics Co (603658.SS) as of Oct 16, 2026 is 254.88 %. In the previous year, Free Cash Flow to Debt Ratio was 154.77 % — a change of 64.69% (higher).

FCF/Debt

254.88 %

YoY

64.69%

Last updated:

Free Cash Flow to Debt Ratio of Autobio Diagnostics Co is 2024 254.88 % . Free Cash Flow to Debt Ratio of Autobio Diagnostics Co was 2023 154.77 % . It decreases by 64.69% higher compared to the previous year.

The Autobio Diagnostics Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2017
68.12 CNY
Jan 1, 2018
251.38 CNY
Jan 1, 2019
10.17 CNY
Jan 1, 2020
-60.29 CNY
Jan 1, 2021
167.49 CNY
Jan 1, 2022
467.85 CNY
Jan 1, 2023
154.77 CNY
Jan 1, 2024
254.88 CNY
The Autobio Diagnostics Co FCF/Debt history
YEARFCF/DebtYoY
254.88 %+64.69%
154.77 %-66.92%
467.85 %+179.33%
167.49 %-377.79%
-60.29 %-693.06%
10.17 %-95.96%
251.38 %+269.02%
68.12 %-24.91%
90.71 %-61.14%
233.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autobio Diagnostics Co Stock analysis

What does Autobio Diagnostics Co do? Autobio Diagnostics Co Ltd, listed on the Shanghai Stock Exchange under ticker 603658.SS, is a healthcare company based in Zhengzhou, China. The company specializes in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. With a workforce of 5,505 employees, Autobio Diagnostics went public on September 1, 2016. Its product portfolio includes immunodiagnostic reagents such as microplate chemiluminescence diagnostic reagents, enzyme-linked immunosorbent assay (ELISA) diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The company also offers microbiology detection products, including training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products encompass microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. Autobio Diagnostics primarily serves domestic markets within China, focusing on providing diagnostic solutions for healthcare applications. The company's headquarters is located in Zhengzhou, Henan Province, and it operates within the healthcare sector, specifically in the health care industry. Its website, https://www.autobio.com.cn/, provides further information on its services and products. Autobio Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autobio Diagnostics Co stock

Free Cash Flow to Debt Ratio of Autobio Diagnostics Co is 254.88 % in 2024.

Free Cash Flow to Debt Ratio of Autobio Diagnostics Co changed from 154.77 % to 254.88 %, representing a 64.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Autobio Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Autobio Diagnostics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Autobio Diagnostics Co

All Key Metrics — Autobio Diagnostics Co